

**TABLE 95** Summary results for the sensitivity analyses for mixed-treatment comparison (HR, 95% CI) for PFS/TTP comparing chemotherapy vs chemotherapy in population 2: population with non-squamous disease

Reference treatment vs comparator	Mixed-treatment comparison 1 (n = 16), HR (95% CI)	Mixed-treatment comparison A (n = 15), HR (95% CI)	Mixed-treatment comparison B (n = 16), HR (95% CI)	Mixed-treatment comparison C (n = 16), HR (95% CI)
GEM + PLAT vs VNB + PLAT <sup>43,45,49,50,54,58</sup>	1.05 (0.92 to 1.19)	1.05 (0.93 to 1.20)	1.06 (0.93 to 1.21)	1.07 (0.93 to 1.22)
GEM + PLAT vs PAX + PLAT <sup>43,46,47,56,60</sup>	1.08 (0.97 to 1.21)	1.08 (0.97 to 1.21)	1.14 (0.99 to 1.30)	1.12 (0.97 to 1.28)
GEM + PLAT vs DOC + PLAT <sup>47</sup>	1.05 (0.89 to 1.24)	1.05 (0.87 to 1.24)	1.05 (0.86 to 1.25)	1.02 (0.84 to 1.22)
GEM + PLAT vs PEM + PLAT <sup>61</sup>	0.90 (0.74 to 1.10)	0.90 (0.73 to 1.11)	0.90 (0.71 to 1.14)	0.90 (0.71 to 1.14)
VNB + PLAT vs PAX + PLAT <sup>43,51</sup>	1.03 (0.89 to 1.22)	1.03 (0.88 to 1.20)	1.07 (0.90 to 1.27)	1.05 (0.88 to 1.24)
VNB + PLAT vs DOC + PLAT <sup>44,52,53</sup>	1.01 (0.85 to 1.18)	0.99 (0.83 to 1.18)	0.99 (0.82 to 1.18)	0.96 (0.79 to 1.14)
VNB + PLAT vs PEM + PLAT	0.86 (0.68 to 1.09)	0.85 (0.67 to 1.09)	0.85 (0.65 to 1.12)	0.84 (0.65 to 1.10)
PAX + PLAT vs DOC + PLAT <sup>47</sup>	0.97 (0.80 to 1.17)	0.97 (0.79 to 1.17)	0.92 (0.74 to 1.13)	0.91 (0.73 to 1.12)
PAX + PLAT vs PEM + PLAT	0.83 (0.66 to 1.04)	0.83 (0.65 to 1.05)	0.79 (0.61 to 1.05)	0.80 (0.62 to 1.06)
DOC + PLAT vs PEM + PLAT	0.85 (0.66 to 1.12)	0.86 (0.66 to 1.14)	0.86 (0.65 to 1.18)	0.88 (0.66 to 1.20)

A HR >1 favours the reference treatment and a HR <1 favours the comparator treatment.